MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Inhibikase Therapeutics EBITDA per Share 2011-2026 | IKT
Annual EBITDA per Share Inhibikase Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.53 | -1.2 | -3.73 | -4.29 | -0.81 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.53 | -4.29 | -2.11 |
Quarterly EBITDA per Share Inhibikase Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.14 | -0.12 | -0.16 | - | -0.66 | -0.67 | -0.75 | - | -0.89 | -1.16 | -1.03 | - | -1.07 | -1.1 | -0.18 | - | -0.18 | -0.21 | -0.26 | - | -0.08 | -0.05 | -0.07 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.05 | -1.16 | -0.488 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-6.85 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-1.68 | $ 3.88 | 3.89 % | $ 9.34 B |  Australia |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.25 | $ 323.46 | -2.98 % | $ 42.4 B | USA |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.11 | $ 4.7 | -0.63 % | $ 766 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
-1.7 | $ 3.55 | 4.26 % | $ 357 M | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-8.81 | $ 8.1 | 9.16 % | $ 80.1 M | USA |
 |
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-0.77 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.05 | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
3.68 | $ 21.91 | 1.04 % | $ 1.02 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-0.95 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
62.6 | $ 101.31 | 1.85 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | USA |
 |
Galectin Therapeutics
GALT
|
-0.31 | $ 2.3 | -10.35 % | $ 147 M | USA |
 |
ContraFect Corporation
CFRX
|
-124 | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
0.1 | $ 1.39 | -10.32 % | $ 357 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
0.87 | $ 8.57 | -1.44 % | $ 6.83 B |  Spain |
 |
Aquestive Therapeutics
AQST
|
-0.66 | $ 4.21 | -0.71 % | $ 450 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 23.86 | -2.93 % | $ 3.04 B | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.38 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-0.99 | $ 1.54 | 3.02 % | $ 410 M | Britain |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B |  Cayman-islands |
|
Immatics N.V.
IMTX
|
-1.37 | $ 10.75 | -2.27 % | $ 676 M | Germany |
 |
Checkpoint Therapeutics
CKPT
|
-1.42 | - | - | $ 169 M | USA |
 |
Incyte Corporation
INCY
|
8.24 | $ 95.06 | -2.11 % | $ 18.6 B | USA |
 |
Caladrius Biosciences
CLBS
|
-2.67 | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
0.24 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
-0.4 | - | - | $ 25.3 M | USA |